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ABSTRACT
Objective To evaluate the eficacy and safety of oral 
levosimendan in patients with amyotrophic lateral 
sclerosis (ALs). This phase II, randomised, double-blind, 
placebo-controlled, crossover, three-period study with 
6 months open-label follow-up enrolled adults with 
ALs and sitting slow vital capacity (sVC) 60%–90 % of 
predicted from 11 sites in four countries.
Methods patients received levosimendan 1 mg daily, 
1 mg two times a day or placebo during three 14-day 
crossover periods and levosimendan 1–2 mg daily during 
open-label follow-up. primary endpoint was sitting sVC; 
secondary endpoints included supine sVC, ALs Functional 
Rating scale-Revised (ALsFRs-R), tolerability and safety.
Results Of 66 patients randomised, 59 contributed 
to the double-blind results and 50 entered open-
label follow-up. sitting sVC was not signiicantly 
different between the treatments. In post hoc analysis 
using period-wise baselines, supine sVC favoured 
levosimendan over placebo, estimated mean differences 
from baseline being −3.62% on placebo, +0.77% on 
levosimendan 1 mg daily (p=0.018) and +2.38% on 
1 mg two times a day (p=0.001). headache occurred 
in 16.7% of patients during levosimendan 1 mg 
daily (p=0.030), 28.6% during 1 mg two times a day 
(p=0.002) and 3.3% during placebo. The respective 
frequencies for increased heart rate were 5.1% 
(p=0.337), 18.5% (p=0.018) and 1.7%. No signiicant 
differences between the treatments were seen for other 
adverse events.
Conclusions Levosimendan did not achieve the primary 
endpoint of improving sitting sVC in ALs. headache and 
increased heart rate were increased on levosimendan, 
although it was otherwise well tolerated. A phase 
III study to evaluate the longer term effects of oral 
levosimendan in ALs is ongoing.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is an adult-
onset neurodegenerative disease of upper and 
lower motor neurons resulting in progressive weak-
ness, with death occurring from respiratory failure 
commonly as a result of diaphragmatic weakness 
typically within 34 years. None of the current 
therapies offer substantial clinical benefit for 
patients with ALS, riluzole having a modest effect 
on survival and edaravone on the rate of functional 
decline.1 Despite the beneficial effects of non-in-
vasive ventilation,2 3 poor respiratory function is 
a major source of disability, fatigue, morbidity and 
mortality in ALS, and there is an urgent need for an 
effective therapy to improve symptoms associated 
with the respiratory decline.
Levosimendan binds selectively to troponin C 
sensitising cardiac and skeletal muscles to calcium,4 
and currently, an intravenous formulation of levosi-
mendan is indicated for the treatment of acute wors-
ening of severe heart failure. The mean elimination 
half-lives of levosimendan and its two active metab-
olites, OR-1855 and OR-1896, are about 1 and 60 
hours, respectively. Due to its having similar free 
plasma concentrations to levosimendan, OR-1896 
is believed to contribute to therapeutic efficacy 
during prolonged treatment (Orion Pharma, data 
on file). Levosimendan does not increase consump-
tion of ATP or oxygen5 and does not cross the 
bloodbrain barrier.6
There is a compelling scientific rationale for 
the development of an oral formulation of levosi-
mendan for symptomatic treatment of ALS. Two 
experimental studies have shown that in diaphragm 
muscle fibres obtained from rats and humans, levo-
simendan improves submaximal force generation 
of diaphragm (both slow and fast muscle fibres) 
by about 15%25%.7 8 In addition, levosimendan 
has been reported to improve neuromechanical 
efficiency of human diaphragm function by 21% 
in healthy people.9 Further support is provided 
by the development programmes of other calcium 
sensitisers, tirasemtiv and reldesemtiv. In a phase IIb 
study, tirasemtiv showed a positive effect on sitting 
slow vital capacity (SVC), but not on the primary 
efficacy endpoint ALS Functional Rating Scale-Re-
vised (ALSFRS-R).10
We therefore carried out a phase two multicentre, 
randomised, double-blind, placebo-controlled trial 
of oral levosimendan in ALS.
METHODS
Study design and participants
This was a randomised, double-blind, place-
bo-controlled, crossover, three-period study with 
6 months open-label follow-up. Each treatment 
period lasted for 2 weeks separated by 1923 day 
washout periods (online supplementary figure 1). 
There were 11 sites from the UK, Germany, Ireland 
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and the Netherlands. The main inclusion criteria were diagnosis 
of definite, probable or laboratory-supported probable ALS 
according to El Escorial revised criteria11; sitting SVC 60%90% 
of predicted for age, height and gender and disease duration 
from symptom onset of 1248 months. The main exclusion 
criteria were other causes of neuromuscular weakness, diagnosis 
of another neurodegenerative disease, assisted ventilation or 
gastrostomy within 3 months and history of significant cardiac 
disease or cardiac events. All entry criteria are listed in the online 
supplementary table 1.
All participants provided written informed consent for the 
study. The study was conducted according to the Declaration 
of Helsinki and in compliance with Good Clinical Practice. 
An independent board monitored safety throughout the study. 
EudraCT number: 2014-004567-21;  ClinicalTrials. gov identi-
fier: NCT02487407.
Study medications, randomisation and dosing
Levosimendan 1 mg capsules and identical placebo capsules were 
used. Patients were randomised to three crossover periods using 
six possible treatment sequences according to Williams design,12 
equal allocation ratio and central randomisation.
Dosing was twice daily. During the 1 mg daily period, levo-
simendan 1 mg was taken in the morning and placebo in the 
evening. During the 2 mg daily period, dosing was 1 mg two 
times a day and during the placebo period, placebo capsules 
were taken two times a day.
During open-label follow-up, all patients were started on 1 
mg levosimendan taken in the morning for 2 weeks, after which 
the dose was increased to 1 mg two times a day if tolerated. The 
dose could be decreased back to 1 mg daily or discontinued if 
required for any reason.
Efficacy assessments
The primary endpoint was SVC (% of predicted normal) 
measured in the sitting position. Secondary endpoints included 
SVC measured supine, sniff nasal pressure (SNP), ALSFRS-R, 
overnight oxygen saturation (SpO
2
), hand grip strength, submax-
imal hand grip strength endurance, Clinical Global Impression 
of Change (CGI-C) assessed by patients and investigators, visual 
analogue scale (VAS) assessing fatigue and quality of life (QoL) 
scales (five-level EuroQoL five dimension (EQ-5D-5L) and Short 
Form-36 (SF-36)). Non-invasive ventilation support, permanent 
continuous ventilator dependence, tracheostomy and survival 
were recorded. During the 6-months open-label follow-up 
period, sitting and supine SVC, SNP, ALSFRS-R, EQ-5D-5L and 
SF-36 were assessed (see online supplementary file and online 
supplementary table 2).
Safety assessments
Safety was assessed by physical examination, vital signs, labora-
tory tests, 12-lead ECG, 24 hours Holter-ECG and recording of 
adverse events (AEs).
Other assessments
Plasma samples for levosimendan, OR-1855, OR-1896 and rilu-
zole concentrations were collected in the morning before study 
treatment intake on days 1 and 14 of each treatment period. 
DNA samples were collected for pharmacogenomic assessments 
and acetylation status, based on polymorphism in the N-acet-
yltransferase enzyme affecting the metabolism of OR-1855 to 
OR-1896. All study assessments are presented in the online 
supplementary table 2.
Statistical analyses
Sample size estimation was based on additional results from the 
BENEFIT-ALS trial.10 SVC was assumed to decline during each 
double-blind crossover period by 4% for placebo and 1% for 
levosimendan, with a common SD of 9% and within subject 
correlation of 0.70. A sample size of 54 provides over 80% 
power at 5% significance.
Intention-to-treat analysis without imputation for missing data 
was used throughout reporting. Appropriate descriptive statis-
tics, frequency tables and plots were used to summarise all data.
The primary efficacy endpoint was change in sitting SVC, 
comparing baseline (period 1 day 1) and day 14 predose assess-
ments. Due to a significant period effect, changes from peri-
od-wise baselines (period 1 day 1, period 2 day 1 and period 3 
day 1, respectively) were analysed as primary comparisons post 
hoc. Analysis of co-variance, appropriate to crossover design, 
was used for primary analysis. The statistical model included 
treatment dose, baseline SVC, treatment sequence and period as 
fixed effects and subject and site as random effects. All pairwise 
comparisons were performed using Tukeys adjustment. Slope 
of decline in SVC was evaluated including all data from both 
double-blind crossover and open-label follow-up using a random 
slope and intercept model.
Secondary efficacy endpoints were primarily evaluated at the 
end of the double-blind crossover. A two-sided 0.05 significance 
level was allocated for the analyses of secondary variables. The 
secondary efficacy variables were analysed using the same statis-
tical principles as the primary variable. Respiratory function and 
quality of life endpoints were evaluated during the open-label 
follow-up using descriptive statistics only.
Levosimendan, OR-1855, OR-1896 and riluzole concentra-
tions were summarised and plotted using descriptive statistics. 
Acetylation status was determined from all subjects participating 
in the study. Acetylation status was summarised by treatments 
and the effects of acetylation status on levosimendan, metabo-
lites, SVC, SNP and ambulatory heart rate (HR) were evaluated 
using analysis of variance (ANOVA) appropriate for the cross-
over design. Potential effects of levosimendan treatment on rilu-
zole concentration were evaluated using ANOVA.
Safety data including AEs, vital signs, laboratory results, 
12-lead ECG and 24 hours Holter-ECG were displayed by treat-
ment and study part (crossover and open label).
RESULTS
Study population
Of the 66 patients randomised, 71.2% were male, 92.4% white 
European and 83.3% had spinal-onset disease. Median disease 
duration from symptom onset was 21.2 months (table 1).
Study medication exposure
During the crossover, double-blind part of the study, 59 patients 
received levosimendan 1 mg daily, 59 levosimendan 1 mg two 
times a day and 58 placebo.
In the open-label follow-up part of the study, 50 people 
received levosimendan, 44 of them increasing the dose from 1 
mg to 2 mg daily at 2 weeks (figure 1). The mean duration of the 
treatment for all study participants was 147.9 days (range 6195 
days) during the open-label follow-up.
Efficacy in the crossover, double-blind part of the study
We initially designed the study under the assumption that patients 
would not deteriorate significantly during the first 3 months and 
therefore that the baseline of the first treatment period would be 
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Table 1 Baseline demographics and characteristics
Variable Total N=66
Age, years
  Median 56.5
  Range 36–75
Sex, n (%)
  Male 47 (71.2)
  Female 19 (28.8)
Weight, kg
  Mean (SD) 76.7 (15.9)
BMI, kg/m2
  Mean (SD) 25.6 (4.0)
Race, n (%)
  Caucasian 61 (92.4)
  Asian 3 (4.5)
  Black 1 (1.5)
  Other 1 (1.5)
Disease duration from symptom onset, months
  Median 21.2
  Range 12–48
Sitting SVC % of predicted
  Mean (SD) 75.3 (9.1)
Supine SVC % of predicted
  Mean (SD) 73.3 (14.0)
ALSFRS-R
  Mean (SD) 36.7 (5.4)
Site of disease onset, n (%)
  Spinal 55 (83.3)
  Bulbar 11 (16.7)
Treated with riluzole, n (%) 66 (100)
ALSFRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; BMI, body 
mass index; SVC, slow vital capacity.
Figure 1 Disposition of subjects. Ae, adverse event.
appropriate to use as baseline for all treatment periods. However, 
due to a significant period effect (p<0.0001) with period-wise 
baseline affected by previous treatment period, the data did not 
allow appropriate interpretation of efficacy using the period 1, 
day 1 baseline for all periods. We therefore performed a post hoc 
period-wise analysis with the period-specific baseline used for each 
period (eg, period 2, day 1 baseline for period 2).
Sitting SVC
Using the original baseline definition, estimated mean differ-
HQFHV IURPEDVHOLQH LQ VLWWLQJ69&ZHUHïIRUSODFHER
ïIRUOHYRVLPHQGDQPJGDLO\S YVSODFHERDQG
ï IRU OHYRVLPHQGDQ  PJ GDLO\ S  YV SODFHER
Using period-wise baselines (post hoc), the differences between 
levosimendan and placebo remained similar (data not shown).
Supine SVC
There is no formula to predict the effects of age, height and 
gender on supine SVC, and expected values were therefore 
calculated using the formula for sitting SVC. Using the orig-
inal baseline definition, mean differences from baseline were 
ï IRU SODFHER ï IRU OHYRVLPHQGDQ  PJ GDLO\
S  YV SODFHER DQG ï SRLQWV IRU OHYRVLPHQGDQ 
PJGDLO\S YVSODFHER8VLQJSHULRGZLVHEDVHOLQHVSRVW
KRFPHDQGLIIHUHQFHVIURPEDVHOLQHZHUHïIRUSODFHER
 IRU OHYRVLPHQGDQ  PJ GDLO\ S  YV SODFHER
and +2.38% points for levosimendan 2 mg daily (p<0.001 vs 
placebo). Supine SVC results using the period-wise baselines 
(post hoc) are presented for each period separately and all the 
periods combined in figure 2 and the results with the primary 
analyses are shown for each period separately in the online 
supplementary figure 2.
Patients with bulbar onset had lower baseline supine SVC than 
patients with spinal onset. In the subgroup analyses, changes 
IURP EDVHOLQH ZHUH GLIIHUHQW GHSHQGLQJ RQ RQVHW VLWH S 
for interaction), the treatment effect being larger in patients with 
EXOEDU RQVHW ï IRU SODFHER  OHYRVLPHQGDQ  PJ
GDLO\S YVSODFHERDQGOHYRVLPHQGDQPJGDLO\
S YVSODFHER1XPHULFDOO\JUHDWHUWUHDWPHQWHIIHFWVZHUH
seen in patients who had baseline supine SVC below the median 
YDOXH RI  SRLQWV S  IRU LQWHUDFWLRQ ï IRU
SODFHERï OHYRVLPHQGDQPJGDLO\ S YVSODFHER
DQGOHYRVLPHQGDQPJGDLO\S YVSODFHER
ALSFRS-R
There was no significant difference in the ALSFRS-R total or 
respiratory scores. Estimated mean differences from baseline 
ZHUH ï IRU SODFHER ï IRU OHYRVLPHQGDQ  PJ GDLO\
S  YV SODFHER DQG ï IRU OHYRVLPHQGDQ  PJ GDLO\
S YVSODFHER(VWLPDWHGPHDQGLIIHUHQFHVIURPEDVHOLQH
LQUHVSLUDWRU\GRPDLQVFRUHVZHUHïIRUSODFHERIRU
OHYRVLPHQGDQ  PJ GDLO\ S  YV SODFHER DQG  IRU
OHYRVLPHQGDQPJGDLO\S YVSODFHER
Other eficacy endpoints
There were no trends seen between placebo and levosimendan 
in SNP, VAS of fatigue, overnight SpO
2
, hand grip assessments, 
CGI-C or in QoL scales
Key efficacy parameters during the 6 months open-label part 
of the study are presented in the online supplementary file.
 o
n
 30 July 2019 by guest. Protected by copyright.
http://jnnp.bmj.com/
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2018-320288 on 17 July 2019. Downloaded from 
4 Al-Chalabi A, et al. J Neurol Neurosurg Psychiatry 2019;0:1–6. doi:10.1136/jnnp-2018-320288
Neuromuscular
Figure 2 slow vital capacity (sVC) (per cent of predicted normal) measured in the supine position. Change from period-wise baselines (period 1 day 
1, period 2 day 1 and period 3 day 1, respectively; post hoc analysis) in per cent predicted sVC is shown for all three 14-day crossover treatment periods 
combined (left) and each period separately (right).
Table 2 Most common adverse events during the study
Preferred term
Double-blind cross-over Open-label follow-up
Levosimendan
1 mg (N=59)
Levosimendan
1 mg two times a day (N=59)
Placebo
(N=58)
Levosimendan
1–2 mg (N=50)
Participants (%)
Headache 10 (16.9)* 17 (28.8)† 2 (3.4) 5 (10.0)
Fall 9 (15.3) 9 (15.3) 5 (8.6) 14 (28.0)
Heart rate increased‡ 3 (5.1)§ 11 (18.6)¶ 1 (1.7) 1 (2.0)
Nasopharyngitis 4 (6.8) 4 (6.8) 3 (5.2) 4 (8.0)
Cough 6 (10.2) – 1 (1.7) 3 (6.0)
Contusion 2 (3.4) 4 (5.1) 1 (1.7) –
Nausea 4 (6.8) 1 (1.7) 1 (1.7) 3 (6.0)
Diarrhoea 1 (1.7) 3 (5.1) 1 (1.7) 3 (6.0)
Constipation 2 (3.4) 2 (3.4) 3 (5.2) 1 (2.0)
Oxygen saturation decreased** 3 (5.1) 4 (6.8) – 1 (2.0)
*P=0.030.
†p=0.002.
‡Preferred terms ‘heart rate increased’, ‘tachycardia’ and ‘sinus tachycardia’ combined.
§P=0.337.
¶P=0.018.
**Decreased oxygen saturation was reported in a total of two patients from two centres.
Tolerability and safety
In the double-blind crossover part of the study, AEs were 
reported by 71% during levosimendan 1 mg daily, 85% levosim-
endan 2 mg daily and 53% of patients on placebo. Most of the 
AEs were mild, with severe AEs reported in isolated cases only. 
The most commonly reported AEs during the crossover part 
were headache, fall and increased HR (terms HR increased, 
tachycardia and sinus tachycardia combined) (table 2). Of 
the 50 patients continuing to open-label follow-up, AEs were 
reported for 42 (84%), with the most commonly reported events 
being fall (28%), dysphagia (12%), respiratory failure (12%), 
headache (10%) and nasopharyngitis (8%).
During the double-blind crossover part of the study, 13 of 
the 66 patients discontinued the study due to an AE, the most 
common reason being increase in HR fulfilling a predefined 
study treatment stopping rule (one during levosimendan 1 mg 
daily, eight during 2 mg daily and one during placebo). Based on 
the 24 hours Holter-ECG, mean changes from baseline in mean 
HR were 5.2 beats per minute (bpm) during levosimendan 1 mg 
GDLO\ESPGXULQJPJGDLO\DQGïESPGXULQJSODFHER
Other AEs leading to discontinuation of the study during the 
FURVVRYHU SHULRGV ZHUH KHDGDFKH Q  DQG DWULDO ILEULOODWLRQ
DQG(&*47SURORQJHGQ GXULQJOHYRVLPHQGDQPJGDLO\
DQGEUDG\FDUGLDDQGFDUGLDFDUUHVWQ GXULQJSODFHER'XULQJ
the open-label follow-up, six subjects discontinued the study due 
to AEs, five of them being serious adverse events (SAEs) (pulmo-
nary embolism, aspiration pneumonia, respiratory failure, acute 
myocardial infarction and dysphagia) and one non-serious AE 
(HR increased).
During the crossover part of the study, SAEs were reported 
in four (7%) patients both during levosimendan 1 mg daily 
and placebo and in two (3%) patients during levosimendan 2 
mg daily. Nineteen patients (38%) reported SAEs during open-
label follow-up. The most commonly reported SAE terms were 
respiratory failure, dysphagia and ALS. Two of the SAEs were 
assessed as related to the study treatment by the investigator: 
bradycardia and cardiac arrest during placebo in the crossover 
part and acute myocardial infarction during the open-label 
follow-up. Five patients died during the study (one during the 
crossover and four during the open-label part of the study); in 
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all cases, the death was assessed as not related to the study treat-
ment by the investigator. Two patients died of ALS and one each 
of pneumonia aspiration, pneumonia bacterial, myocardial 
infarction and pneumothorax and respiratory failure.
Mean changes from baseline in supine systolic blood pres-
VXUH ZHUH QXPHULFDOO\ JUHDWHU DIWHU OHYRVLPHQGDQ IURP ï
WRïPP+JWKDQDIWHUSODFHERIURPWRïPP+J
Changes in diastolic blood pressure were similar to those in 
systolic blood pressure. No differences were seen in mean ortho-
static test results between treatments.
Levosimendan, OR-1855, OR-1896 and riluzole concentrations
Slow acetylators had higher OR-1855 concentrations, but lower 
OR-1896 concentrations than rapid acetylators (online supple-
mentary table 3). Samples taken after the washout period did not 
indicate any carryover effects. Acetylation status had no effect on 
VXSLQH69&HIIHFWREVHUYHGLQWHUDFWLRQS WKHDSSDUHQW
treatment effect being similar in slow (2 mg daily 2.05%, 1 mg 
GDLO\DQGSODFHERïDQGIDVWPJGDLO\
PJGDLO\ïDQGSODFHERïDFHW\ODWRUV
There were no differences in plasma concentrations of riluzole 
between day 1, day 14 or between the treatment periods (data 
not shown).
DISCUSSION
This was the first study with oral levosimendan in patients with 
ALS. The study was designed to find treatment differences within 
a short period of time with three crossover periods during double-
blind comparison. Fourteen-day treatment periods were selected 
based on earlier studies reporting that a single oral 1 mg dose of 
levosimendan was able to increase cardiac output in patients with 
severe heart failure by 22% (p<0.005; Orion Pharma data on file) 
and that a short levosimendan infusion improved diaphragm func-
tion in healthy people.9 It was expected, however, that most of the 
outcome measures such as ALSFRS-R13 and QoL scales would not 
show any differences within 14-day periods.
In contrast to our primary assumptions, there was a clear 
period effect (but no carryover effect) seen in the crossover part 
of the study, and therefore the efficacy results were analysed 
period-wise, using period-specific baselines (post hoc analyses). 
Although the primary endpoint of sitting SVC did not show 
significant differences between the treatments, supine SVC in 
the post hoc analyses indicated a dose-related treatment effect 
favouring levosimendan against placebo (4.39% points differ-
ence between placebo and levosimendan 1 mg and 6.00% 
points difference between placebo and 2 mg). Similar results 
were seen during all three periods, effectively replicating the 
findings two further times, thus strengthening our confidence 
in the results (figure 2). Diaphragmatic performance is reduced 
more dramatically by lying than by sitting, and the first clinical 
signs of respiratory insufficiency often appear during sleeping or 
when lying down.14 15 Seeing differences between the treatments 
in supine but not sitting SVC is supported by the finding that 
in patients with ALS, supine vital capacity is a more sensitive 
measure of diaphragmatic strength than that measured in the 
upright position, suggesting that upright vital capacity might 
not reveal abnormalities becoming noticeable in the supine 
position.16 There is also evidence that supine vital capacity is 
a better predictor of survival than upright vital capacity,17 18 
and among several different respiratory measures, it has been 
reported to correlate most closely with diaphragmatic weakness, 
especially in patients with vital capacity <75% of predicted.16 
Treatment effects seen in supine SVC between levosimendan 
and placebo treatments in patients with SVC <75% predicted at 
baseline are in line with this expectation. Although no significant 
changes were seen, both the ALSFRS-R total score and respi-
ratory domain subscore numerically favoured levosimendan, 
supporting the supine SVC results. However, one needs to be 
cautious in interpreting ALSFRS-R results as the absolute differ-
ences were small and the treatment duration was short. Apart 
from supine SVC, other secondary efficacy endpoints did not 
show any difference between treatments.
All 50 patients completing the crossover part of the study 
continued to the open-label follow-up. Mean supine SVC at 
study baseline was 73.3% points and declined to 61.8% points 
at the end of the 6 months open-label follow-up. In turn, mean 
ALSFRS-R total score was 36.7 points at baseline and declined 
to 28.9 points at the end of open-label follow-up. During the 
entire 9-months study, the mean decline in supine SVC and 
ALSFRS-R total score were 1.93% points/month and 1.03 
points/month, respectively. Mean declines were smaller over the 
last 6 months when all patients were on levosimendan. Based 
on a previous retrospective analysis, slowing the rate of decline 
RI69&E\SRLQWPRQWKO\IURPïWRïDQGWR
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respiratory events or death.19 In light of this analysis, our results 
are encouraging, but no conclusions can be drawn since our 
uncontrolled data from the open-label follow-up are not directly 
comparable due to differences in study design and duration, and 
the position in which SVC was measured.
In patients with rapid acetylator status more active metabolite 
OR-1896 of levosimendan is formed20 and the active metabolite 
levels were higher in rapid than slow acetylators in this study. 
Despite this, there was no difference in the change of supine 
SVC. This is in line with the earlier findings in patients with 
heart failure, in whom haemodynamic effects were similar in 
rapid and slow acetylators.20
Levosimendan was generally well tolerated. Headache and 
increase in HR were more common during levosimendan treatment 
than placebo showing a dose-dependent increase in frequency. 
Headache, most probably due to vasodilatation by levosimendan, 
was usually short lasting and did not result in discontinuation of 
the study except for one patient with a medical history of migraine. 
In most cases, the increase in HR was reported as an AE based on 
a predefined study treatment stopping rule (increase in mean HR 
of over 15 bpm from baseline in the 24 hours Holter recording) 
and was not due to subjective symptoms of tachycardia. Most 
of the other frequently reported AEs, such as falls, nasopharyn-
gitis, dysphagia and respiratory failure, were not considered to be 
related to the study treatment, reflecting the signs and symptoms 
of ALS. Supraventricular and ventricular tachyarrhythmias were 
reported in a low number of patients and were evenly distributed 
across the treatment arms. AEs such as dizziness or somnolence 
were reported as isolated events only and no AEs such as ataxia, 
agitation, confusion or delirium were reported in the study. All 
deaths and most other SAEs were assessed as not related to the 
study treatment by the investigator, indicating incidental events 
expected to be related to ALS.
In summary, we found no evidence that levosimendan 
improves SVC in the sitting position. Levosimendan treatment 
was well tolerated but with a dose-dependent increase in head-
ache and tachycardia compared with placebo. In the light of the 
post hoc analysis indicating a possible dose-dependent treat-
ment effect of levosimendan on the supine SVC compared with 
placebo, a phase III study is ongoing to evaluate longer term 
effects of oral levosimendan in ALS (NCT03505021) (online 
supplementary video).
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